Template:SwitchMAO

From Psychiatrienet
Revision as of 16:21, 14 April 2026 by Joost (talk | contribs)
Jump to: navigation, search
  • Tranylcypromine and fenelzine are irreversible MAO inhibitors for MAO-A and MAO-B. Fenelzine has higher affinity for MAO-A, whereas tranylcypromine has higher affinity for MAO-B. Side effects could occur during a switch. In addition, monitoring of sodium levels is adviced.[1]
  • Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension.
  • Known side effects in fenelzine are oedema and/or increased liver enzyme levels.
  • It is adviced to admit the patient in a mental health care clinic for intensive monitoring during this switch.
  • A van Diepen et al. De lange mars van farma naar patiënt Medisch Contact May 2021